Adam Durbin

20PUBLICATIONS
185CO-AUTHORS
Predictive and prognostic markersSolid tumoursHaematological tumoursMolecular targetsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 20, 2026
Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300.

|Mar 28, 2026
Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Katie E Hebron, Patience Odeniyide, Yun Wei

|Mar 26, 2026
Dominant clones leverage developmental epigenomic states to drive ependymoma.

Alisha S Kardian, Hua Sun, Siri Ippagunta

|Mar 18, 2026
Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers.

D Bennett, M Wierdl, S Chakraborty

|Dec 07, 2025
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.

Angelica Barreto-Galvez, Mrunmai Niljikar, Julia Elizabeth Gagliardi

|Jun 13, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Steven G DuBois, Lucas Moreno, John Anderson

Pageof 4

Frequent Collaborators

8 joint publications

Jun Qi

7 joint publications

Brian J Abraham

4 joint publications

Neekesh V Dharia

3 joint publications

Mark W Zimmerman